260 related articles for article (PubMed ID: 29289494)
1. Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation.
Miyazawa K; Pastori D; Lip GYH
Prog Cardiovasc Dis; 2018; 60(4-5):537-541. PubMed ID: 29289494
[TBL] [Abstract][Full Text] [Related]
2. Clinical Impact of Oral Anticoagulation in Patients with Atrial High-rate Episodes.
Marinheiro R; Parreira L; Amador P; Lopes C; Fernandes A; Mesquita D; Farinha J; Fonseca M; Duarte T; Caria R
J Stroke Cerebrovasc Dis; 2019 Apr; 28(4):971-979. PubMed ID: 30642667
[TBL] [Abstract][Full Text] [Related]
3. Rationale and Design of the Evaluation of Oral Anticoagulation for Reduction of Thrombo-embolism in Chinese Patients with Device-Detected Subclinical Atrial Fibrillation (ART-CAF) Trial: an Open-Label Registry-Based Clinical Trial.
Yang Y; Xu F; Tong J; Cai L; Jiang W; Sheng X; Pan Y; Jiang J; Zhang J; Jiang D; Zhao L; Fu G
Cardiovasc Drugs Ther; 2018 Aug; 32(4):389-396. PubMed ID: 30027309
[TBL] [Abstract][Full Text] [Related]
4. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
Kirchhof P; Blank BF; Calvert M; Camm AJ; Chlouverakis G; Diener HC; Goette A; Huening A; Lip GYH; Simantirakis E; Vardas P
Am Heart J; 2017 Aug; 190():12-18. PubMed ID: 28760205
[TBL] [Abstract][Full Text] [Related]
5. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
[TBL] [Abstract][Full Text] [Related]
6. Role of cardiovascular implantable electronic devices in delivering individualized disease-guided management of patients with non-valvular atrial fibrillation and high bleeding risk.
Mascarenhas DAN; Sharma M; Ziegler PD; Kantharia BK
Acta Cardiol; 2019 Apr; 74(2):131-139. PubMed ID: 29863432
[TBL] [Abstract][Full Text] [Related]
7. Are atrial high rate episodes (AHREs) a precursor to atrial fibrillation?
Khan AA; Boriani G; Lip GYH
Clin Res Cardiol; 2020 Apr; 109(4):409-416. PubMed ID: 31522249
[TBL] [Abstract][Full Text] [Related]
8. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort.
Shantsila E; Wolff A; Lip GY; Lane DA
Br J Gen Pract; 2015 Jan; 65(630):e16-23. PubMed ID: 25548312
[TBL] [Abstract][Full Text] [Related]
9. Atrial high-rate episodes and stroke prevention.
Camm AJ; Simantirakis E; Goette A; Lip GY; Vardas P; Calvert M; Chlouverakis G; Diener HC; Kirchhof P
Europace; 2017 Feb; 19(2):169-179. PubMed ID: 28172715
[TBL] [Abstract][Full Text] [Related]
10. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence.
Bertaglia E; Blank B; Blomström-Lundqvist C; Brandes A; Cabanelas N; Dan GA; Dichtl W; Goette A; de Groot JR; Lubinski A; Marijon E; Merkely B; Mont L; Piorkowski C; Sarkozy A; Sulke N; Vardas P; Velchev V; Wichterle D; Kirchhof P
Europace; 2019 Oct; 21(10):1459-1467. PubMed ID: 31377792
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry.
Bakhai A; Darius H; De Caterina R; Smart A; Le Heuzey JY; Schilling RJ; Zamorano JL; Shah M; Bramlage P; Kirchhof P
Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):299-305. PubMed ID: 29474715
[TBL] [Abstract][Full Text] [Related]
12. Oral anticoagulation for subclinical atrial tachyarrhythmias detected by implantable cardiac devices: an international survey of the AF-SCREEN Group.
Boriani G; Healey JS; Schnabel RB; Lopes RD; Calkins H; Camm JA; Freedman B
Int J Cardiol; 2019 Dec; 296():65-70. PubMed ID: 31327519
[TBL] [Abstract][Full Text] [Related]
13. Predicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF) Study.
Nasir JM; Pomeroy W; Marler A; Hann M; Baykaner T; Jones R; Stoll R; Hursey K; Meadows A; Walker J; Kindsvater S
Heart Rhythm; 2017 Jul; 14(7):955-961. PubMed ID: 28506913
[TBL] [Abstract][Full Text] [Related]
14. Device-detected atrial fibrillation: what to do with asymptomatic patients?
Chen-Scarabelli C; Scarabelli TM; Ellenbogen KA; Halperin JL
J Am Coll Cardiol; 2015 Jan; 65(3):281-94. PubMed ID: 25614426
[TBL] [Abstract][Full Text] [Related]
15. Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the "Low-Risk" Patients?
Manolis AS; Manolis TA; Manolis AA; Melita H
Curr Drug Targets; 2017 Nov; 18(16):1852-1865. PubMed ID: 27593686
[TBL] [Abstract][Full Text] [Related]
16. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation.
Overvad TF; Larsen TB; Albertsen IE; Rasmussen LH; Lip GY
Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1619-29. PubMed ID: 24215192
[TBL] [Abstract][Full Text] [Related]
17. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Galanis T; Merli GJ
Hosp Pract (1995); 2013 Feb; 41(1):26-36. PubMed ID: 23466965
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
[TBL] [Abstract][Full Text] [Related]
19. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
[TBL] [Abstract][Full Text] [Related]
20. Detection of subclinical atrial fibrillation with cardiac implanted electronic devices: What decision making on anticoagulation after the NOAH and ARTESiA trials?
Boriani G; Gerra L; Mei DA; Bonini N; Vitolo M; Proietti M; Imberti JF
Eur J Intern Med; 2024 May; 123():37-41. PubMed ID: 38281819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
